|
v**********m
发帖数: 5516 | 2 这个是爆雷。
SB公司，在这个大环境下搞增发，能卖个好价钱吗？ |
|
|
K********g
发帖数: 9389 | 4 估计是早就谈好了，在12号左右就谈好了。
对这样的股票要敏感，做短线的话，无缘无故涨了，就要卖掉。
无缘无故涨的，必西施，例如之前的DCTH |
|
K********g
发帖数: 9389 | 5 估计西施价在2.8-3.0
大家要买还是等到2.5吧，我说的2.1可能比较难 |
|
|
|
|
|
K********g
发帖数: 9389 | 10 DCTH年底上8没问题，你现在不买，过几天就后悔了 |
|
|
v**********m
发帖数: 5516 | 12 Jefferies & Company, Inc. 也是Dcth增发的券商。 |
|
f**********g
发帖数: 2252 | 13 还是老牛经验丰富，上次你提醒后卖掉了。
晚上给你发包子。 |
|
y*****l
发帖数: 5997 | 14 http://www.thestreet.com/_yahoo/story/11215926/1/biotech-calend
Updated with corrected FDA approval decision date for Roche's melanoma drug
Zelboraf. It's Oct. 28, 2011, not Nov. 11, 2011, as previously reported.
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated
and extended through the first quarter of 2012.
For easier reference, this regulatory calendar is organized in chronological
order based on the drug approval decision date. Information on pending FDA
advisory pan... 阅读全帖 |
|
|
y*****l
发帖数: 5997 | 16 11:55 Do you think there is > 50% chance someone buys HGSI in next 12 mos.?
Yes
( 68% )No
( 32% )
Thursday October 20, 2011 11:55
11:56 adam feuerstein: Hello! Welcome to the October edition of Biotech
Stock Live Chat.
Thursday October 20, 2011 11:56 adam feuerstein
12:02 adam feuerstein: hi everyone
Thursday October 20, 2011 12:02 adam feuerstein
12:02 adam feuerstein: I'll get started in a minute or so, let folks log in
.
Thursday October 20, 2011 12:02 adam feuerstein
12:02 adam feuers... 阅读全帖 |
|
K********g
发帖数: 9389 | 17 【 以下文字转载自 Stock 讨论区 】
发信人: KeepBuying (雁过留声), 信区: Stock
标 题: 2011年11月-2012年1月的FDA的NDA医药股
发信站: BBS 未名空间站 (Wed Nov 2 00:25:56 2011, 美东)
既然成为板斧了，那就为股版添点东西。
下面的医药股是2011年11-2012年1月的FDA的NDA待审批的。大家记住，任何药股的NDA
风险都比较大，要学会炒药股，切忌去赌药股的NDA.下面带星号的我觉得还可以值得研
究。
12/8/2011 Antares Pharma Inc. AIS Anturol Gel (NDA) FDA decision
on Anturol Gel for overactive bladder
12/7/2011 AFFYMAX INC AFFY Peginesatide (NDA) FDA panel to
review Peginesatide for anemia associated with chronic... 阅读全帖 |
|
y*****l
发帖数: 5997 | 18 22 Hot Drugs Facing FDA Approval in 2012
By Adam Feuerstein 11/29/11 - 08:55 AM EST
BOSTON (TheStreet) -- Here's your first look at the biotech and
pharmaceutical companies with pending FDA drug approval decisions in 2012.
The calendar on the following pages captures nearly two-dozen U.S.
regulatory events -- FDA drug approvals and advisory panels -- expected
between December 2011 and July 2012. As every savvy biotech investor and
trader knows, the volatility in biotech and drug stocks ramps sig... 阅读全帖 |
|
|
|
b*****h
发帖数: 783 | 21 Libigel trial 失败，大瀑布来了。 |
|
|
|
|
|
|
w*********7
发帖数: 2883 | 27 Trading on this security is currently halted.
不让买 |
|
|
j*****2
发帖数: 306 | 29 why BPAX still a buy after the trail is fail?
even 50cent?? |
|
b*****h
发帖数: 783 | 30 because it is too cheap and it still has some other assets |
|
|
l*********m
发帖数: 16971 | 32 幸亏跑掉了，看来要每天追踪光头，炸弹随时爆
，但和这几天大盘相比，还是很坚挺。
豫一会就下到了2.2下，后来在2.17卖了。
of
a |
|
j*****2
发帖数: 306 | 33 OK, buy 50K shares, try try. |
|
|
j*****2
发帖数: 306 | 35 sold 16K share at 54cent, keep rest for 65 to 70cent tomorrow. |
|
j*****2
发帖数: 306 | 36 sold another 16000share at 59cent , ha |
|
|
y*****l
发帖数: 5997 | 38 报导日期：2011/12/15 07:11
美股期指上涨
美股期指周四盘前上涨，投资人等待美国公布一连串经济数据，并关注欧洲与中国的制
造业指数。道琼工业指数期货盘前上涨49点或0.4%，为11,812点；标普500指数期货上
涨5.9点或0.5%，为1,211.9点；Nasdaq 100指数期货上涨8.75点或0.4%，为2,237.75点
。
瑞士央行宣布，将欧元兑瑞郎波动下限维持在1.2瑞郎，继续扞卫此关卡；即便如此，
瑞郎还是全面上涨。
欧债难解，华尔街股市周三收盘连续三天走跌，道琼工业指数收盘下挫131.46点或1.1%
，为11,823.48点。
美国今早将公布多项数据，包括上周初领失业金人数、11月份生产者物价、12月纽约州
制造业指数、经常帐收支。9:15将公布11月份工业生产、10点将公布FED费城制造业指
数。
BioSante Pharmaceuticals Inc. (*BPAX*)开盘後股价可能狂泻，因为公司公布治疗女
性性功能障碍的新药物实验失败，未能达到预定目标。
半导体设备商Novellus Systems Inc.(*NVLS*)与Lam ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 39 How about their FDA?
BioSante has a scheduled FDA decision date for its product candidate, Bio-T-
Gel, on 02/14/2012. The company is partnered with Teva (TEVA) on Bio-T-Gel,
which is a once-daily transdermal testosterone gel in development for the
treatment of male hypogonadism, or low testosterone levels. In 2010, the
transdermal testosterone market for men in the U.S. was over $1.2 billion.
BPAX currently trades around $2.50 with the highest sell-side analyst one
year price target being $6. |
|
|
f**********g
发帖数: 2252 | 41 来自主题: _pennystock版 - Bpax BioSante (BPAX) 发表LibiGel第三阶段临床实验数据为正面，独立数据监督委员会(
DMC)完成第9次的第三阶段临床实验的心血管事件与乳癌安全研究审查。DMC的建议是
LibiGel安全研究应该按照FDA协定内容继续进行。 |
|
